share_log

Bright Minds Is Unaware of Any Material Changes

Bright Minds Is Unaware of Any Material Changes

明智之腦不知道有任何重大變化
newsfile ·  2024/10/15 21:09

Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm that the Company's management is unaware of any material changes in the Company's operations that would account for the recent increase in market activity.

溫哥華,不列顛哥倫比亞省--(資訊來源:新聞稿發佈機構 - 2024年10月15日)- 在CIRO的請求下,Bright Minds Biosciences Inc.(cse: DRUG)(納斯達克: DRUG)("Bright Minds"或"公司")希望確認公司管理層對公司運營未發生任何可以解釋最近市場活動增加的重大變化。

About Bright Minds

關於Bright Minds

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds' drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first- generation compounds, such as fenfluramine, psilocybin, LSD, and ibogaine.

Bright Minds專注於開發新型革命性治療方法,用於神經精神障礙、癲癇和疼痛。Bright Minds擁有一系列設計用於靶向神經迴路異常的下一代5-羥色胺激動劑,這些異常是難以治療的疾病如難治性癲癇、難治性抑鬱症、創傷後應激障礙和疼痛的責任。該公司利用其世界一流的科學和藥物研發專業知識,推出下一代安全有效的藥物。Bright Minds的藥物旨在潛在保留迷幻劑和其他羥色胺類化合物的有效療法特性,同時最小化副作用,從而創造出比第一代化合物如芬氟拉明、溴麥角鹼、LSD和伊波甘更勝一籌的優質藥物。

Investor Contact:

投資者聯繫人:

Ian McDonald
CEO and Director
E: ian@brightmindsbio.com
T: (647) 865-8622

Ian McDonald
首席執行官和董事
E: ian@brightmindsbio.com
T: (647) 865-8622

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

加拿大證券交易所未對本新聞發佈內容進行覈准或駁回。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論